Beyond Immunosuppression: The Rise of T-Cell Engagers for Autoimmune Disease | Dr. Jeffrey Jones, MD, MPH - Chief Medical Officer, Cullinan Therapeutics

Send us Fan MailFor decades we've treated autoimmune diseases by suppressing the immune system - but what if we've been approaching the problem all wrong? What if, instead of lifelong immunosuppression, we could selectively eliminate the immune cells causing disease and allow the immune system to rebuild itself? Today we're exploring one of the hottest areas in biotechnology: T-cell engagers and the possibility of an "immune reset."Dr. Jeffrey Jones, MD, MPH is Chief Medical Officer of Cullinan Therapeutics ( https://cullinantherapeutics.com/ ) and one of the leaders helping bring the power of T-cell engager therapies beyond cancer and into autoimmune disease. With more than two decades of experience spanning academia and industry, Dr. Jones has been at the forefront of clinical development in hematology, oncology, and immunology.Prior to joining Cullinan, Dr. Jones served as Vice President of Global Drug Development at Bristol Myers Squibb, leading programs in lymphoma and myeloid diseases and helping guide the lifecycle strategy for Reblozyl®. Earlier, he held leadership positions at Celgene, where he developed clinical strategies across lymphoma and chronic lymphocytic leukemia portfolios.Before entering industry, Dr. Jones spent more than a decade at The Ohio State University, where he led the Chronic Lymphocytic Leukemia clinical research program and served as Associate Professor of Internal Medicine. Today, he is helping pioneer a new generation of T-cell engagers designed not to continuously suppress the immune system, but potentially to reset it - opening the possibility of durable, treatment-free remission for diseases such as rheumatoid arthritis, lupus, lupus nephritis, and autoimmune cytopenias.Dr. Jones earned his MD from the University of Michigan Medical School, an MPH from the University of Texas School of Public Health, and an MBA from The Ohio State University Fisher College of Business.#AutoimmuneDisease #Lupus #RheumatoidArthritis #Immunology #TCellEngagers #Biotechnology #DrugDevelopment #PrecisionMedicine #ImmuneSystem #ImmuneReset #ClinicalTrials #Biotech #HealthcareInnovation #FutureOfMedicine #ProgressPotentialPossibilitiesSupport the show